Epidemiology, Public Health, Environmental and Occupational Health
48
Scopus Publications
1419
Scholar Citations
23
Scholar h-index
34
Scholar i10-index
Scopus Publications
Vaccination Coverage and Factors Associated With Incomplete Vaccination Schedules in Children Under 5 in a Peripheral Area of the Federal District of Brazil Ivea Rayane Mendes Nicacio Viana, Henry Maia Peixoto Public Health Nursing, 2026 Objective To estimate vaccination coverage (VC) and analyze the factors associated with the incomplete vaccination schedule (IVS) in children under 5 years of age in two Basic Health Units in the Federal District of Brazil. Design A cross‐sectional study. Sample The study included 162 children in two Basic Health Units; 54.94% were male, and all were under 5 years of age. Measurements Guardians were interviewed using a structured questionnaire, and their vaccination booklets were photographed. VC was estimated and prevalence ratios (PR) were calculated using Poisson regression analysis. Results Twenty percent of the children had an IVS. None of the vaccines evaluated reached the VC considered correct in terms of age and interval between doses. Factors associated with IVS were age under 2 years (adjusted PR: 2.55; 95% CI: 1.53–4.24), difficulties arising from the COVID‐19 pandemic (adjusted PR: 2.71; 95% CI: 1.51–4.86) and a negative response when asked whether all vaccines were administered in the same location (adjusted PR: 1.97; 95% CI: 1.13–3.44). Conclusions A high proportion of children presented IVS, associated with factors such as age, lack of continuity of vaccination in the same location and difficulties caused by the COVID‐19 pandemic.
Hospitalization costs of patients with severe acute respiratory infections due to COVID-19 in a public teaching hospital: a micro-costing approach Ana Carolina Esteves da Silva Pereira, Luciana G. Gallo, Ana Flávia de M. Oliveira, Maria Regina F. de Oliveira, Emanuelly Martins da Silva, Henry M. Peixoto Brazilian Journal of Infectious Diseases, 2026 OBJECTIVE: To estimate the costs associated with the hospitalization of patients with Severe Acute Respiratory Infection (SARI) due to SARS-CoV-2 in a university hospital affiliated with the Brazilian Unified Health System (SUS) in 2020 and 2021. METHODS: A bottom-up micro-costing approach was used to conduct a cost analysis based on data from a hospital clinical cohort. Patients with confirmed diagnoses of COVID-19 and SARI, admitted to general wards or intensive care units (with or without mechanical ventilation), were included. Healthcare activities were categorized as hospitalization, ventilation, hemodialysis, nutrition, medications, and laboratory tests. Costs were calculated based on individualized consumption of supplies and procedures, also considering the annualized cost of equipment. Comparisons were made between micro-costing and macro-costing (based on the Hospital Admission Authorizations - AIH). RESULTS: A total of 627 patients were analyzed. The total cost was R$ 5,824,366.73 (Int$ 2,307,593.80) when healthcare professionals were excluded and R$19,437,731.25 (Int$ 7,701,161.35) when they were included. Medications accounted for the largest share (52.79%). Micro-costing was 1.7-times higher than macro-costing for hospital costs alone and 2.3-times higher when professional costs were included. Multivariate analysis identified length of hospital stay as the main factor associated with increased costs, while age, sex, and referral origin showed no significant association. CONCLUSION: This study reveals the substantial economic impact of COVID-19-related hospitalizations in high-complexity care settings. It also highlights the importance of improving financing models for the SUS, particularly given the discrepancies between actual costs and federal reimbursement values. These findings contribute to the development of public policies and response strategies for future health emergencies.
Referral of people with low back pain to physical therapists in Brazilian primary healthcare: A challenge revealed Tais Luciana Lacerda, Pedro Lacerda Montes, Luciana Gazzi Macedo, Raymond Ostelo, Henry Maia Peixoto, Rodrigo Luiz Carregaro Brazilian Journal of Physical Therapy, 2026 BACKGROUND: Low back pain (LBP) is a disabling condition worldwide, and current evidence suggests low rates of referral to physical therapists and extensive use of low-value interventions such as pharmacological treatments and emergency visits. OBJECTIVE: To investigate the frequency of referrals and characterize people with LBP accessing primary care physical therapists, as well as characterize clinical and sociodemographic aspects and the use of health resources in Brazil. METHOD: Observational study using nationwide data on 1,459,710 adults with LBP, stratified according to G1: medical care only, G2: medical care and referral to physical therapist, G3: physical therapist as first contact. Data were analyzed descriptively. RESULTS: 1,405,145 people with LBP were included in G1, followed by G2 (N:14,079), and G3 (N:40,486). The majority was female (56.3 %), and the average age was 49 (±17) years for females and 48 (±17) for males. Less than 1 % (G2) were referred to physical therapists. Of these, 8085 (57.4 %) had an average duration of 17.4 days (±65.6) between referral and their clinical appointment, and 5994 (42.6 %) had a longer duration (261.1 ± 146.9 days). A total of 130,570 (8.9 %) participants were referred for imaging, totaling 152,150 exams. G1 had 105.65 exams/1000 people and 128 referrals to specialists/1000 people. G2 had 196.32 exams and 384.76 referrals to specialists/1000 people, and G3 had 22.87 exams and 64.89 referrals to specialists/1000 people. CONCLUSION: We found a relatively low number of referrals of people with LBP to physical therapists in primary health care in Brazil, and a long period between the referral and the first contact with this professional. In addition, diagnostic imaging and referral to a specialist were frequently used.
Cost-Utility Analysis of the Treatment With Ataluren Plus Standard of Care Compared With Standard of Care Alone in Patients With Duchenne Muscular Dystrophy in Brazil Eliane W. Roesch, Verônica Colpani, Grace Anne A. Dória, Klébya Hellen D. de Oliveira, Catia Oliveira, Henry M. Peixoto, Ana Flávia de M. Oliveira Value in Health Regional Issues, 2026 OBJECTIVES: to evaluate the cost-utility of ataluren plus standard of care (SoC) for treating patients with nonsense mutation Duchenne muscular dystrophy from the Brazilian public health system perspective. METHODS: A semi-Markov model, comprising 5 states, was developed to estimate the incremental cost per quality-adjusted life-years (QALYs) of ataluren plus SoC compared with SoC alone. A 48-year time horizon was used in the base-case analysis, considering annual cycles. Costs were expressed as international dollars (Int$) applying the purchasing power parity conversion rate (Brazilian purchasing power parity of 2.44 BRL/Int$ in 2023). The transition probabilities and utility data were obtained from previous studies, and costs were based on data from a microcosting study and the Brazilian Drug Market Regulation Chamber. Both costs and QALYs were discounted using a rate of 5%. Parameter uncertainty was assessed through deterministic and probabilistic sensitivity analyses. RESULTS: Ataluren plus SoC leads to incremental 0.503 QALYs and incremental costs of Int$13 298 877.45, resulting in an incremental cost-utility ratio of Int$26 415 910.08/QALY. According to the deterministic sensitivity analysis, utilities related to the state's health progression of the model were the parameter that most significantly influenced the incremental cost-utility ratio. In the probabilistic sensitivity analysis, all estimates were above the current willingness-to-pay threshold of Int$49 180.33 per QALY for rare diseases. CONCLUSIONS: Ataluren plus SoC for treating nonsense mutation Duchenne muscular dystrophy patients was not a cost-effective intervention compared with SoC alone from the perspective of the Brazilian public health system.
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care Rodrigo Luiz Carregaro, Ângela Jornada Ben, Aline Martins de Toledo, Yara Andrade Marques, Caroline Ribeiro Tottoli, Raymond Ostelo, Henry Maia Peixoto, Judith E. Bosmans Expert Review of Pharmacoeconomics and Outcomes Research, 2026 BACKGROUND: Low back pain (LBP) is a disabling condition affecting all age groups globally. Exercise is safe and cost-effective for managing LBP. Pilates is an effective exercise modality recommended for LBP but is not reimbursed by the Brazilian Public Health System. This study aimed to estimate the budget impact of implementing Pilates for LBP patients within the Brazilian public health system compared to usual care. RESEARCH DESIGN AND METHODS: A budget impact analysis (BIA) was conducted over a five-year horizon, from healthcare and societal perspectives. Costs were extracted in local currency and converted to international dollars using purchasing power parities. Deterministic sensitivity analyses were performed. RESULTS: Over five years, healthcare costs in the usual care were Int$860.8 million, while Pilates reached Int$958 million, resulting in an incremental impact of Int$97.2 million. From the societal perspective, the usual care cost was Int$4.32 billion, and the Pilates scenario was Int$4.15 billion, indicating savings of Int$172.2 million. The incremental budget impact was negative, meaning that Pilates would provide savings of Int$172,203,216. CONCLUSION: Implementing a group-based Pilates program for LBP in the Brazilian public health system would increase healthcare costs by Int$97 million but generate societal savings of Int$172 million over five years.
The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System Henry Maia Peixoto, Luiza Lena Bastos Gottin, Jose Diego de Brito-Sousa, Vanderson Sampaio, Penny Grewal Daumerie, Elodie Jambert, Wuelton Monteiro, Marcus V.G. Lacerda, Angela Devine Lancet Regional Health Americas, 2025 Background Vivax malaria requires radical cure to clear both the blood-stage and liver-stage parasites. Brazil, like most endemic countries, has been prescribing a 7-day primaquine regimen for radical cure without testing for glucose-6-phosphate-dehydrogenase (G6PD) deficiency to exclude those at risk of primaquine-induced haemolysis. Tafenoquine, a new single-dose drug for radical cure requires G6PD screening before prescription to ensure safety. This study aims to assess the cost-effectiveness of prescribing tafenoquine after semi-quantitative G6PD screening from the Brazilian Public Health System perspective. Methods A decision tree model was developed for adults presenting with vivax malaria over 12-months. The tafenoquine strategy of semi-quantitative G6PD testing before prescription of single-dose tafenoquine to those with ≥70% G6PD activity was compared with: (1) current practice : 7-day low-dose primaquine (0.5 mg/kg/day) without G6PD screening and (2) primaquine screening strategy: 7-day low-dose primaquine (0.5 mg/kg/day) for patients with ≥30% G6PD activity determined by semi-quantitative G6PD screening. The primary outcome was the cost per disability-adjusted life-year (DALY) averted, compared with the Brazilian willingness-to-pay threshold of US$7752 (R$40,000). Findings The tafenoquine strategy was US$2894 (R$14,934) per DALY averted compared to current practice , well below the willingness-to-pay threshold. The tafenoquine strategy dominated the primaquine screening strategy , averting 0.14 DALYs with cost savings of US$13 (R$66). In both comparisons, the tafenoquine strategy had a >98% likelihood of being cost-effective. Interpretation The prescription of tafenoquine to those who test G6PD normal with a semi-quantitative test is a cost-effective strategy for the radical cure of vivax malaria in Brazil. While the cost-effectiveness in other settings may vary due to differences in costs and the epidemiology of vivax malaria and G6PD deficiency, the robustness of these findings should be reassuring, particularly where healthcare facilities expect to see a large number of patients annually. Funding Medicines for Malaria Ventures.
Advanced Access in Primary Healthcare and Its Effects on Emergency Department Utilization: A Rapid Review Rafael Tannure, Salma Sarkis, Amanda Peres, Juliana de Souza Lapa, Lígia Villela Rodrigues, Italo Landim, Ciro Martins Gomes, Katia Crestine Poças, Henry Maia Peixoto, Sandro Rogério Rodrigues Batista, Rodolfo Deusdará Healthcare Switzerland, 2025 Background: The advanced access (AA) scheduling model in primary healthcare (PHC) may reduce unnecessary visits to the emergency department (ED). However, evidence of this effect remains uncertain and limited. Objective: To evaluate whether the adoption of AA models in PHC may reduce ED visits, when compared to the traditional model. Methods: A rapid review of the literature according to the World Health Organization’s guidelines was performed, using two databases (PubMed and Lilacs) with articles from 1980 to 2023. Results: A total of 1286 articles were found according to our search. Of them, 1245 were excluded based on their titles, most of them due to not evaluating advanced accesses as an intervention. Of the remaining 41 articles, many did not evaluate ED visits as an outcome, nor did they have the criteria of inclusion. Eight articles evaluated ED visits as an outcome and had inclusion criteria. Five articles were included and three found an association between the adoption of advanced access in PHC and a reduction in ED visits. Conclusion: This review shows that the adoption of AA in PHC may reduce ED visits. However, it is essential to carry out new studies to understand the relationship between the adoption of AA in PHC and its outcomes in universal healthcare systems.
Factors Associated with Post-COVID Cardiac Conditions and Potential Prognostic Factors: A Systematic Review Lidian Franci Batalha Santa Maria, Josicélia Estrela Tuy Batista, Virginia Kagure Wachira, Wenderval Borges Carvalho Junior, Alexandre Anderson de Sousa Munhoz Soares, Isis Polianna Silva Ferreira de Carvalho, Henry Maia Peixoto Life, 2025 Cardiac conditions are a significant category of post-COVID conditions. The objective of this study was to synthesise the evidence on the factors associated with the development of post-COVID cardiac conditions, the frequency of clinical outcomes in affected patients, and the potential prognostic factors. A systematic review was conducted using the databases EBSCOhost, MEDLINE via PubMed, BVS, and Embase, covering studies from 2019 to December 2023. A total of 8343 articles were identified, and seven met the eligibility criteria for data extraction. The protective effect of vaccination stood out among the associated factors, showing a reduced risk of developing post-COVID cardiac conditions. Conversely, COVID-19 reinfections were associated with an increased risk of cardiovascular outcomes. Regarding the main outcomes in these patients, most recovered, although some cases persisted beyond 200 days of follow-up. The study included in the analysis of prognostic factors reported that the four children who did not recover by the end of the study were between two and five years old and had gastrointestinal symptoms during the illness. The COVID-19 vaccination regimen reduces the risk of developing post-COVID cardiac conditions. Public health policies promoting immunisation should be encouraged to prevent SARS-CoV-2 infections and reinfections.
Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis Marcio Coutinho Xavier Naves, Angelica Amorim Amato, Ivan Ricardo Zimmermann, Henry Maia Peixoto Lancet Regional Health Americas, 2025 Background: Heart failure, a complex clinical syndrome with high morbidity and mortality, has become a significant burden on public health. Recently, a new class of antidiabetic agents-the sodium-glucose cotransporter 2 (SGLT2) inhibitors-was associated with a significant reduction on mortality and hospitalization in HF with reduced ejection fraction (HFrEF) when added to standard pharmacological treatment. Considering the lack of data on its cost-effectiveness, the present study aims to estimate the incremental cost-effectiveness ratio of add-on dapagliflozin treatment for HFrEF from the Brazilian public healthcare system perspective. Methods: We built a Markov model to estimate the clinical outcomes and costs of 1,000 hypothetical subjects with established HFrEF in a lifetime horizon. The model inputs were based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial and local data. The main outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained. Deterministic and probabilistic sensitivity analyses, as well as scenario analyses, were performed. Findings: The addition of dapagliflozin to standard care treatment in 1,000 HFrEF patients yielded an expected value of 366.99 additional QALYs at an incremental cost of US$ 1,517,878.49, resulting in an ICER of US$ 4,136.08 per QALY gained, being a cost-effective strategy considering the Brazilian official cost-effectiveness threshold (US$ 8,000/QALY). In probabilistic sensitivity analyses, 96.60% of the simulations were also cost-effective. In the scenario analyses, results were similar for individuals with and without diabetes. Interpretation: Dapagliflozin is likely to be cost-effective when added to standard HFrEF therapy in Brazil. Funding: This study was supported by the National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliação de Tecnologias em Saúde-IATS).
Costs of Guillain-Barré Syndrome in the Brazilian Federal District: the patients' perspective Ana Flávia de Morais Oliveira, Luciana Gerra Gallo, Mábia Milhomem Bastos, Amanda Amaral Abrahão, Klauss Kleydmann Sabino Garcia, Jeane Kelly Silva de Carvalho, Lilian de Paula Macedo, Wildo Navegantes de Araújo, Henry Maia Peixoto Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022
Snakebite envenomation in the Brazilian Amazon: A cost-of-illness study Samara Freire Valente Magalhães, Henry Maia Peixoto, Jacqueline de Almeida Gonçalves Sachett, Sâmella S Oliveira, Eliane Campos Alves, Hiochelson Najibe dos Santos Ibiapina, Wuelton Marcelo Monteiro, Maria Regina Fernandes de Oliveira Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020
Rattlesnakes bites in the Brazilian Amazon: Clinical epidemiology, spatial distribution and ecological determinants Hildegard Loren Rebouças Santos, José Diego de Brito Sousa, João Arthur Alcântara, Jacqueline de Almeida Gonçalves Sachett, Thiago Soares Villas Boas, Ivan Saraiva, Paulo Sergio Bernarde, Samara Freire Valente Magalhães, Gisely Cardoso de Melo, Henry Maia Peixoto, Maria Regina Oliveira, Vanderson Sampaio, Wuelton Marcelo Monteiro Acta Tropica, 2019
Cost of visceral leishmaniasis care in Brazil Isis Polianna Silva Ferreira de Carvalho, Henry Maia Peixoto, Gustavo Adolfo Sierra Romero, Maria Regina Fernandes de Oliveira Tropical Medicine and International Health, 2017
G6PD deficiency in Latin America: Systematic review on prevalence and variants Wuelton M Monteiro, Fernando FA Val, André M Siqueira, Gabriel P Franca, Vanderson S Sampaio, Gisely C Melo, Anne CG Almeida, Marcelo AM Brito, Henry M Peixoto, Douglas Fuller, Quique Bassat, Gustavo AS Romero, Oliveira Maria Regina F, Lacerda Marcus Vinícius G Memorias do Instituto Oswaldo Cruz, 2014
Hospitalization costs of patients with severe acute respiratory infections due to COVID-19 in a public teaching hospital: a micro-costing approach ACE da Silva Pereira, LG Gallo, AFM Oliveira, MRF de Oliveira, ... The Brazilian Journal of Infectious Diseases 30 (3), 105819 , 2026 2026
Temperature as a Climate Variable in Dengue Epidemiological Studies TFPLA Silva, WM Ramalho, HM Peixoto, MAV Correia, ALS Oliveira Revista da Sociedade Brasileira de Medicina Tropical 59, e0481-2025 , 2026 2026
Cost-Utility Analysis of the Treatment With Ataluren Plus Standard of Care Compared With Standard of Care Alone in Patients With Duchenne Muscular Dystrophy in Brazil EW Roesch, V Colpani, GAA Dória, KHD de Oliveira, C Oliveira, ... Value in Health Regional Issues, 101623 , 2026 2026
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care RL Carregaro, Â Jornada Ben, AM de Toledo, YA Marques, CR Tottoli, ... Expert review of pharmacoeconomics & outcomes research 26 (1), 77-85 , 2026 2026
Temperature as a Climate Variable in Dengue Epidemiological Studies TFP da Silva, L Alves, WM Ramalho, HM Peixoto, MAV Correia Junior, ... REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL 59 , 2026 2026
Vaccination Coverage and Factors Associated With Incomplete Vaccination Schedules in Children Under 5 in a Peripheral Area of the Federal District of Brazil IRMN Viana, HM Peixoto Public Health Nursing , 2026 2026
Referral of people with low back pain to physical therapists in Brazilian primary healthcare: A challenge revealed TL Lacerda, PL Montes, LG Macedo, R Ostelo, HM Peixoto, RL Carregaro Brazilian Journal of Physical Therapy 30 (1), 101538 , 2026 2026
PD59 Inpatient Healthcare Costs And Neonatal Disorders: Insights From The Brazilian Public Health System A Toledo, JR Moura, EB Freire, HM Peixoto, EN da Silva, SA Pereira, ... International Journal of Technology Assessment in Health Care 41 (S1), S63-S63 , 2025 2025
OP58 Cost Utility Of Ataluren Plus Standard Care In Patients With Nonsense Mutations Duchenne Muscular Dystrophy In Brazil EW Roesch, V Colpani, GA Dória, KHD de Oliveira, C Oliveira, ... International Journal of Technology Assessment in Health Care 41 (S1), S28-S28 , 2025 2025
ID 340-Sustentabilidade e Custo para Aquisição de Inseticidas Utilizados no Programa de Vigilância, Prevenção e Controle do Aedes aegypti no Brasil (2002 A 2023) TFP de Lima Alves, KB Campos, WM Ramalho, HM Peixoto Epidemiologia e Serviços de Saúde: Revista do Sistema Unico de Saúde do … , 2025 2025
ID 85-Panorama da Formação e Produção Científica relacionada à Avaliação Econômica em Saúde no Brasil AF de Morais Oliveira, EN da Silva, YA Marques, JP Maia, I Zimmermann, ... Epidemiologia e Serviços de Saúde: Revista do Sistema Unico de Saúde do … , 2025 2025
Healthcare Costs and Main Characteristics of Childbirth and Neonatal Inpatient Care From the Brazilian Public Health System Perspective JR Moura, EB Freire, HM Peixoto, EN da Silva, SA Pereira, RL Carregaro, ... Value in health regional issues 50, 101161 , 2025 2025 Citations: 1
The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System HM Peixoto, LLB Gottin, JD de Brito-Sousa, V Sampaio, PG Daumerie, ... The Lancet Regional Health–Americas 51 , 2025 2025 Citations: 1
Tendências na incidência e letalidade da dengue: análise de séries temporais interrompida, Brasil, 2001-2022 TFPLA Silva, HM Peixoto, LRS Freitas, ELL Araújo, WM Ramalho Epidemiologia e Serviços de Saúde 34, e20240424 , 2025 2025 Citations: 2
Trends in dengue incidence and lethality: interrupted time series analysis, Brazil, 2001-2022 TFPLA Silva, HM Peixoto, LRS Freitas, ELL Araújo, WM Ramalho Epidemiologia e Serviços de Saúde 34, e20240424 , 2025 2025
Advanced Access in Primary Healthcare and Its Effects on Emergency Department Utilization: A Rapid Review R Tannure, S Sarkis, A Peres, JS Lapa, LV Rodrigues, I Landim, ... Healthcare 13 (12), 1430 , 2025 2025
Factors Associated with Post-COVID Cardiac Conditions and Potential Prognostic Factors: A Systematic Review LFBS Maria, JET Batista, VK Wachira, WBC Junior, AASM Soares, ... Life 15 (3), 388 , 2025 2025 Citations: 1
Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis MCX Naves, AA Amato, IR Zimmermann, HM Peixoto The Lancet Regional Health–Americas 42 , 2025 2025 Citations: 3
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019 E Batista Freire, H Maia Peixoto, KM Almeida Ayupe, E Nunes da Silva, ... Expert review of pharmacoeconomics & outcomes research 25 (1), 81-89 , 2025 2025 Citations: 2
ID 340-Sustentabilidade e Custo para Aquisição de Inseticidas Utilizados no Programa de Vigilância, Prevenção e Controle do Aedes aegypti no Brasil (2002 A 2023) TFPLA Silva, KB Campos, WM Ramalho, HM Peixoto Epidemiologia e Serviços de Saúde 34 (S1) , 2025 2025
MOST CITED SCHOLAR PUBLICATIONS
Prevalência e fatores associados à depressão entre idosos institucionalizados: subsídio ao cuidado de enfermagem ER Silva, ARP Sousa, LB Ferreira, HM Peixoto Revista da Escola de Enfermagem da USP 46, 1387-1393 , 2012 2012 Citations: 150
G6PD deficiency in Latin America: systematic review on prevalence and variants WM Monteiro, FFA Val, AM Siqueira, GP Franca, VS Sampaio, GC Melo, ... Memórias do Instituto Oswaldo Cruz 109, 553-568 , 2014 2014 Citations: 123
Serological diagnosis of canine visceral leishmaniasis in B razil: systematic review and meta‐analysis HM Peixoto, MRF de Oliveira, GAS Romero Tropical Medicine & International Health 20 (3), 334-352 , 2015 2015 Citations: 96
Systematic review of factors associated with the development of Guillain–Barré syndrome 2007–2017: what has changed? VK Wachira, HM Peixoto, MRF de Oliveira Tropical Medicine & International Health 24 (2), 132-142 , 2019 2019 Citations: 93
Snakebite envenomation in the Brazilian Amazon: a descriptive study SFV Magalhães, HM Peixoto, N Moura, WM Monteiro, MRF de Oliveira Transactions of The Royal Society of Tropical Medicine and Hygiene 113 (3 … , 2019 2019 Citations: 75
Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes WM Monteiro, GP Franca, GC Melo, ALM Queiroz, M Brito, HM Peixoto, ... Malaria Journal 13 (1), 70 , 2014 2014 Citations: 70
Stepping into a dangerous quagmire: Macroecological determinants of Bothrops envenomings, Brazilian Amazon JA Alcântara, PS Bernarde, J Sachett, AM da Silva, SF Valente, ... PloS one 13 (12), e0208532 , 2018 2018 Citations: 54
Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review VK Wachira, CM Farinasso, RB Silva, HM Peixoto, MRF de Oliveira Global Epidemiology 5, 100098 , 2023 2023 Citations: 42
Prevalence and factors associated with depression among institutionalized elderly individuals: nursing care support ER Silva, ARP Sousa, LB Ferreira, HM Peixoto Revista da Escola de Enfermagem da USP 46, 1387-1393 , 2012 2012 Citations: 40
Cost of visceral leishmaniasis care in Brazil IPSF de Carvalho, HM Peixoto, GAS Romero, MRF de Oliveira Tropical Medicine & International Health 22 (12), 1579-1589 , 2017 2017 Citations: 37
Snakebite envenomation in the Brazilian Amazon: a cost-of-illness study SFV Magalhães, HM Peixoto, J de Almeida Gonçalves Sachett, ... Transactions of The Royal Society of Tropical Medicine and Hygiene 114 (9 … , 2020 2020 Citations: 36
Validation of the rapid test Carestart (tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon MAM Brito, HM Peixoto, ACG Almeida, MRF Oliveira, GAS Romero, ... Revista da Sociedade Brasileira de Medicina Tropical 49 (04), 446-455 , 2016 2016 Citations: 36
Ten epidemiological parameters of COVID-19: use of rapid literature review to inform predictive models during the pandemic LG Gallo, AFM Oliveira, AA Abrahao, LAM Sandoval, YRA Martins, ... Frontiers in public health 8, 598547 , 2020 2020 Citations: 33
Epidemiological burden of Chikungunya fever in Brazil, 2016 and 2017 ERN Vidal, LCV Frutuoso, EC Duarte, HM Peixoto Tropical Medicine & International Health 27 (2), 174-184 , 2022 2022 Citations: 31
Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon HM Peixoto, MAM Brito, GAS Romero, WM Monteiro, MVG de Lacerda, ... Malaria journal 15 (1), 82 , 2016 2016 Citations: 29
Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil MRF de Oliveira, SP Giozza, HM Peixoto, GAS Romero Malaria journal 11 (1), 390 , 2012 2012 Citations: 29
Guillain–Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study HM Peixoto, GAS Romero, WN de Araújo, MRF de Oliveira Transactions of the royal society of tropical medicine and hygiene 113 (5 … , 2019 2019 Citations: 27
G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study HM Peixoto, MAM Brito, GAS Romero, WM Monteiro, MVG de Lacerda, ... Malaria Journal 14 (1), 126 , 2015 2015 Citations: 27
Learning strategies used by undergraduate and postgraduate students in hybrid courses in the area of health HM Peixoto, MM Peixoto, ED Alves Revista Latino-Americana de Enfermagem 20, 551-558 , 2012 2012 Citations: 27
Another piece of the Zika puzzle: assessing the associated factors to microcephaly in a systematic review and meta-analysis LG Gallo, J Martinez-Cajas, HM Peixoto, ACES Pereira, JE Carter, ... BMC Public Health 20 (1), 827 , 2020 2020 Citations: 26
